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POPULAR SCIENCE SUMMARY OF THE THESIS 
The goal of all medical research should be to advance knowledge in order to be able to offer 
effective treatment or preventive measures for diseases. In neurology there has, until recently, 
been treatment available for very few disorders. Examples of recent advances are better drugs 
to minimize the symptoms in multiple sclerosis and trombolytic therapy for cardiovascular 
diseases such as stroke. 
This thesis focusses on genetic diseases caused by defects in single genes, monogenic 
disorders. Also for this category of conditions, novel treatments are emerging. For spinal 
muscular atrophy, the number one genetic killer in children, intense research has led to 
treatments that are very promising. Reports are also coming of a future treatment for 
Huntington disease, a devastating neurodegenerative disease caused by a toxic protein, where 
the defective gene is silenced using advanced molecular therapy. 
A prerequisite for developing treatment for a disease is that the exact cause and mechanisms 
underlying the development of symptoms are known. This makes a correct diagnosis of 
utmost importance, but diagnosing rare diseases is a challenging task. In recent years 
diagnostic possibilities have improved at an increasing pace due to rapid developments in 
several areas. Most importantly, the possibilities of genetic diagnostics have improved 
immensely. Just ten years ago one had to guess what disease the patient had on clinical 
grounds and then look at the genetic sequence of the corresponding gene, if known, a process 
that could take months. But many disorders are not possible to pinpoint in that way, some 
disorders are caused by defects in one of several genes, and other diseases have unspecific 
symptoms. Recent advances have made it possible to, instead of sequencing individual genes, 
sequence all the genes in the human genome simultaneously. The resulting data, often several 
tens of gigabytes in size, is impossible to inspect manually. Instead the data undergoes a 
bioinformatic pipeline of a series of computer algorithms that is aimed at “finding the needle 
in the haystack”. An important part of this process is to apply a predefined filter of genes that 
could fit with the disease under investigation, this filter can consist of any number of genes. 
Other diagnostic advances in recent years are improved imaging capabilities with magnetic 
resonance tomography and positron emission tomography, and improved possibilities for 
advanced biochemical analysis to look for aberrations in metabolites and proteins. 
In this thesis three new very rare monogenic disorders are described. One disease affects the 
muscles and leads to severe loss of function. Another disease, spinocerebellar ataxia, leads to 
impaired balance and coordination and failure to control several body functions, including 
instable blood pressure. The third disease is a rare defect in an enzyme affecting important 
biochemical processes in the body, adenosine kinase deficiency. Persons affected by this 
disorder become both intellectually and physically impaired at an early age. For two of these 
disorders the genetic defect is now known, and light has been shed on some of the 
mechanisms involved in generating symptoms. It is my sincere hope that the findings 
described here will contribute to the eventual development of treatments for the disorders.  
ABSTRACT 
This thesis is about improving diagnosis and treatment to persons affected by rare diseases. 
Diagnosis before treatment is a principle often told to medical students. But what if a 
diagnosis can’t be made with the resources and knowledge at hand? The number of disorders 
where the genetic background and the molecular mechanisms are known is increasing rapidly 
with the advent of massive parallel sequencing, but there are still many disorders awaiting 
genetic and biological characterization. In my PhD project I have tried to contribute to 
characterization of new rare diseases, and in two cases this was successful all the way to 
finding the causative mutations. The success owes a great deal to two things, the access to 
massive parallel sequencing platforms and to the extensive resources available through my 
workplace, Centre for Inherited Metabolic Disorders, CMMS.  
Paper I is the detailed description of a rare muscle disease, Sarcoplasmic body myopathy. The 
first description of a family from Sweden affected by this condition was published by our 
group 40 years ago and paper II provides comprehensive clinical investigations of nine 
individuals. 
Paper II is about the genetic and molecular characterization of the disorder, leading to the 
finding of the responsible gene, MB encoding myoglobin, and description of an additional 
five families. In paper II we also claim that the damage to muscle cells is caused by oxidative 
damage. 
Paper III provides a detailed clinical description of the first two Swedish families affected by 
spinocerebellar ataxia type 4, SCA4. Besides ataxia and polyneuropathy striking autonomic 
dysfunction was found, expanding the phenotype significantly. By linkage analysis, custom 
capture and sequencing we could narrow down the genomic region of interest. Further studies 
are ongoing in order to identify the causative gene  
Paper IV involves the clinical, biochemical and genetic characterization of a novel inborn 
error of metabolism, adenosine kinase deficiency, ADK. The two Swedish siblings affected 
by this disorder had an unusual biochemical abnormality, elevated methionine. After 
excluding all known causes of hypermethioninemia we could show that the siblings, as well 
as four additional patients from two unrelated families, were suffering from a previously 
unknown metabolic defect in the methionine cycle. 
Paper V constitutes a proof-of-concept study on how rapid diagnosis can be established in 
acutely ill infants in the neonatal intensive care unit, using customized, rapid whole genome 
sequencing. Babies with metabolic disorders often respond to treatment provided that 
diagnosis can be made before permanent damage to the central nervous system and other 
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Monogenic diseases are individually rare or ultra-rare, but the number of disorders is very 
high, and their collective prevalence is therefore considerable. In Europe a disease is 
considered rare if less than 1 in 2000 people are affected and in total there is an estimated 
number of 6000 to 7000 rare diseases (1). Many, but not all, rare diseases have a genetic 
cause. The symptoms often start during childhood, but over 50% of rare diseases first appear 
in adult life (1). For 6545 disorders there is a known genetic defect (2). In 70% of rare 
diseases neurologic symptoms are present (3).  
Neurology has traditionally been a specialty characterized by and largely limited to detailed 
observation of the disease course with careful documentation of symptoms and clinical signs. 
A diagnosis was established by defining the constellation of symptoms and clinical signs 
together with the specifics of the disease course. During my PhD project, which has been 
ongoing for ten years, the advancements of the methodologies in genetics and molecular 
biology have been spectacular. From painstakingly slow Sanger sequencing of individual 
genes, or fragments of genes, whole exome or genome sequencing (WES or WGS) is now a 
part of routine diagnostics.  
The purpose of this PhD project has been to help patients with undetermined neurological 
diseases to get a specific diagnosis. The motivation is that patients without a diagnosis tend to 
suffer more than patients who have specific diagnoses, due to the burden of uncertainty. A 
specific diagnosis may also result in opportunities for treatment.  Inherited neurological 
disorders comprise a wide spectrum of conditions with involvement of the nervous system as 
the common denominator. Traditionally neuromuscular disorders involving striated skeletal 
muscles, the neuromuscular junction and the peripheral nerves, are also considered 
neurological diseases.   
The PhD project consists of four parts. The first includes the characterization of sarcoplasmic 
body myopathy (SBM), a dominantly inherited late-onset muscular dystrophy. The second 
project involves the detailed clinical phenotyping and linkage analysis of a family with late-
onset spinocerebellar ataxia. The third project includes description of the clinical and 
biochemical phenotype and subsequent elucidation of the molecular mechanism behind 
adenosine kinase deficiency. Finally, the fourth project is aimed at facilitating rapid genetic 
diagnosis for acutely ill neonates and infants with potentially treatable neurological 
conditions in the neonatal intensive care unit, using whole genome sequencing.  
All studies have been performed in a collaborative, multidisciplinary environment. My role 
has been the clinician-scientist’s, with responsibility for patient selection and management, 
clinical work-up, selection of biochemical and genetic investigations, overall coordination, 
interpretation and compilation of results. The team also includes experts in e.g., genetics, 





1.1 INHERITED MYOPATHIES 
Inherited myopathies can be caused by various genetic defects. When unspecific structural 
abnormalities are seen in either light- or electron microscopy the disorder is referred to as a 
muscle dystrophy, and when the morphology is normal the term myopathy is used. Inherited 
myopathies have been classified in different ways over the years. The first classifications date 
back to the late 19th century when Erb coined the term “dystrophia muscularis progressive”. 
Modern classifications often take several aspects of the disease groups into account including 
genetic defect, symptom distribution, age at debut and morphology. 
Congenital muscle dystrophies comprise over 20 different, mostly recessively inherited,  
disorders and affects collectively roughly 1/100 000 individuals (4). The distinguishing 
features in this group are early onset hypotonia, dystrophic muscle and increased creatinine 
kinase (CK). There is often involvement of other organs e.g. in muscle eye brain disease (5). 
Congenital myopathies share the early debut, and the often recessive inheritance with the 
congenital dystrophies, but are characterized by lack of dystrophic features in muscle biopsy. 
Around 1/25 000 are affected by congenital myopathies (6). There are, however, often other 
distinguishing morphological findings, e.g. cores in central core myopathy. Patients with 
these disorders generally have normal CK. The group includes more than 20 separate 
disorders and are, in general, non-progressive. 
The dystrophinopathies Duchenne and Becker muscular dystrophy are more common, 
affecting 15-20/100 000 boys age 5-9 years (7, 8). Symptoms start at age 4-7 with muscle 
weakness most pronounced in the lower extremities. Ambulation is lost in early teens and 
later respiratory failure and cardiomyopathy follow. The disorder is caused by almost 
complete lack (Duchenne) or reduced amounts (Becker) of functioning dystrophin, a protein 
linking the contractile elements to other structural proteins. The biopsy in dystrophinopathies 
shows general dystrophic features and absent or reduced staining for dystrophin. CK is 
commonly very high. 
Limb-girdle myopathies, LGMD, is a large group of disorders containing both autosomal 
dominant and recessive disease. The former classification distinguished the inheritance 
pattern naming the dominant disorders LGMD1 followed by a letter and the recessive as 
LGMD2 followed by a letter, e.g. LGMD2I for the recessively inherited muscle dystrophy 
with defect in fukutin-related protein (FKRP). The disease group had to be re-classified 
recently when the disorder LGMD2Z was characterized and the letters of the alphabet were 
exhausted. The current system uses the term LGMD followed by the letter D (dominant) or R 
(recessive) followed by the defective gene or protein, e.g. LGMD2I is now named LGMD R9 
FKRP-related (9). Symptoms in these disorders typically start in proximal muscles in legs, 
hips and shoulders. Debut is often in the teens, but there is a great variability. Muscle biopsy 
shows unspecific dystrophic changes but sometimes the defective protein can be identified, 
e.g. by reduced staining in Western blot for dysferlin in LGMD R2 dysferlin-related (formerly 
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LGMD2B). CK is generally elevated in these disorders, ranging from mild elevation to very high 
values. The prevalence of LGMD varies in different populations and the collective prevalence is 
not known, but has been estimated to be somewhere between 1-7/100 000 (4, 10). 
 
Figure 1. Illustration of the degree of dystrophic features and muscle symptoms of some of the major disease 
groups in inherited myopathies. On the horizontal axis the proximal to distal involvement is shown and the 




1.1.2 Myopathies with inclusions 
Below are some examples of myopathies where inclusions are seen in muscle biopsies. The 
list is far from complete but serves as a comparison to distinguish from the unique inclusions 
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1.1.2.1 Welander distal myopathy 
Welander distal myopathy (OMIM 604454) is common in Sweden and Finland. In Sweden it 
is sometimes referred to as “Hedesundasjukan” due to the high prevalence in the small village 
Hedesunda. In mid-Sweden and Finland the overall gene frequency is roughly 1/10 000 but in 
the surroundings of Hedesunda it was estimated to be as high as 1/10 (12). The disorder is of 
late onset, usually between 40 and 60 years of age and starts with weakness of the long 
extensors of the hand affecting fine motor skills. Later in the disease course weakness of foot 
extensors ensues. The histopathological findings include, apart from unspecific myopathic 
changes, inclusions of rimmed vacuoles and autophagic vacuoles in both degenerating and 
normal fibers. The genetic origin remained elusive until 2013 when a Finnish group found the 
causative genetic defect, a c.1150G>A, p.E384K transition in the TIA1 gene (13). A Swedish 
group, working in parallel, found the same genetic defect through exome sequencing and 
proceeded to study splicing effects. They found increased SMN2 exon 7 skipping and 
hypothesized that, although increased skipping of exon 7 in SMN2 probably did not play a 
pathogenetic role, the finding could reflect a more widespread splicing dysfunction in muscle. 
The group also calculated that the ancient founder mutation causing the disorder had 
appeared first around 1050 years ago (14). 
  
Figure 2. Morphology of muscle in Welander distal myopathy. A. Rimmed vacuole in a slightly atrophic muscle 
fiber (haematoxylin and eosin stain). B. Electron micrograph of anterior tibial muscle showing an autophagic 
vacuole containing myelin bodies surrounded by normal myofilaments. Magnification 7000×. Reprinted with 
permission (15). 
1.1.2.2 Sporadic inclusion body myositis, sIBM 
This is typically a late onset disorder starting after age 50 in 80% of patients. There is also a 
male preponderance which is more pronounced in higher ages of onset. Women with the 
disorder tend to have an earlier age of debut. Symptoms typically start with knee extensor 
weakness; other common symptoms are flexor weakness in the distal upper extremities and 
swallowing difficulties. The disorder usually progresses slowly and can be considered an 
intermediate between an inflammatory myopathy and a degenerative muscle disease. Muscle 
biopsy in IBM shows inflammation with mononuclear cell infiltration, degenerative changes 
and inclusions. The infiltrated cells are mainly CD8+ cytotoxic T-cells (16). The inclusions 
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found in this disorder are rimmed vacuoles and protein inclusions including amyloid-β as in 
Alzheimer disease (17). 
  
A   B 
Figure 3. Typical morphological findings in sIBM. A. Endomysial inflammatory infiltrates (haematoxylin and 
eosin stain). B. Invasion/compression of a non‐necrotic fiber by inflammatory cells (haematoxylin and eosin 
stain). Reprinted with permission (18).  
1.1.2.3 Hereditary inclusion body myositis, HIBM 
HIBM, often referred to as GNE-myopathy (OMIM 605820), is a recessive disorder where 
most cases have mutations in the GNE gene. The highest prevalence is in the Jewish Persian 
population in the middle east (HIBM) and in Japan (previously Nonaka distal myopathy, now 
considered HIBM), with common founder mutations in the GNE gene present in the 
respective populations (19, 20). The onset of symptoms is earlier than in sIBM, usually in the 
late teens. In contrast to sIBM, the quadriceps muscle is often spared, while other muscles of 
the lower extremity display both weakness and atrophy. The histopathological findings are 
similar to what is found in sIBM, including rimmed vacuoles and accumulation of amyloid-β 
(21).  
The gene GNE encodes UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine 
kinase, a bifunctional enzyme involved in sialic acid synthesis and possibly leading to 
hyposialylation of proteins. It has therefore been hypothesized that substitution with oral 
sialic acid may slow disease progression. Prophylactic treatment in a mouse model of HIBM 
showed that development of a a myopathic phenotype could be prevented by administration 
of sialic acid (22). However, a double blind placebo controlled phase 3 study failed to show 




Figure 4. Overview of sialic acid metabolism. The metabolic defect is in the bifunctional enzyme UDP–GlcNAc-
2‐epimerase/N‐acetylmannosamine kinase, that catalyzes the first two and rate‐limiting steps of the sialic acid 
biosynthetic pathway. N-Acetyl-D-mannosamine (ManNAc) can enter the sialic acid pathway immediately 




Figure 5. A. Hematoxylin and eosin stain of a representative HIBM muscle biopsy. There is increased variation 
in fiber size, angulated atrophic fibers, and fibers bearing cytoplasmic vacuoles (arrowheads). Scale bar = 20 μm. 
B. Electron micrograph showing a subsarcolemmal collection of typical 15–21 nm filaments. Scale bar = 300 
nm. C. Left, confocal microscope image showing an HIBM abnormal muscle fiber with a cytoplasmic inclusion 
immunoreactive with anti‐amyloid β (Aβ) antibody. Scale bar = 10 μm. Right, two abnormal muscle fibers 
(arrowhead) with cytoplasmic inclusions immunopositive with the SMI‐31 antibody recognizing 
hyperphosphorylated tau protein. Scale bar = 20 μm. D. By Western blot analysis, in HIBM muscle, NCAM 
migrates as a discrete band of ≈130 kDa, whereas in control myopathies (Duchenne muscular dystrophy in this 
case) NCAM migrates as a broad band of ≈150–200 kDa. This evidence suggests abnormal sialylation of 
NCAM in HIBM muscle. Reproduced with permission (24). 
1.1.2.4 Myofibrillar myopathies 
Myofibrillar myopathies (MFM) is a group of rare mostly dominantly inherited disorders. 
They share some microscopic similarities consisting of inclusions of aggregates of abnormal 
sarcomeric proteins, e.g. actin, myosin, desmin, myotilin, filamin C and Z-band proteins 
beginning at the Z-disk. Most patients with MFM experience symptoms late in life, typically 




Figure 6. Cartoon highlighting the proteins involved in 
myofibrillar myopathies. The myofibrillar proteins 
constituting the myofibrils (filamin C, myotilin, Z-band 
alternatively spliced PDZ-containing protein, four-and-a-half 
LIM domain 1, Bcl-2-associated athanogene-3) are 
scaffolded by the extramyofibrillar proteins (desmin, aB-
crystallin, plectin) that also link the myofibrils to nuclei, 
sarcolemma and mitochondria. Also included in the cartoon 
is the linkage to the structural proteins required to transmit 
the contractile force to the extracellular matrix, and the 
ubiquitin–proteasome and the autophagic–lysosomal systems 
essential for breakdown of abnormal proteins. Reproduced 




Figure 7. Histopathological findings in 
myofibrillar myopathies (MFMs). A. 
Hematoxylin & eosin (H&E)  and B. Gomori 
trichrome (G-Tri) (B) staining in 
desminopathy. Arrows indicate the presence of 
isolated sarcoplasmic and subsarcolemmal 
protein aggregates (bars = 50 mm). C. H&E  
and D. G-Tri staining in myotilinopathy and in 
a patient with MFM of unknown aetiology, 
respectively. Note the vacuolar changes 
(arrows) in myotilinopathy (bar = 75 mm) and 
the polymorphic protein aggregates in MFM of 
unknown aetiology (bar = 50 mm). E. Succinic 
dehydrogenase and F. cytochrome-C oxidase 
(F) staining in desminopathy. Reproduced with 
permission (25).  
 
 
A typical example of a myofibrillar myopathy is MFM 9, Hereditary myopathy with early 
respiratory failure (HMERF, OMIM 603689), a disorder sometimes referred to as Edström 
myopathy since it was first described in Sweden in 16 individuals from 7 families (26). This 
disorder is inherited as an autosomal dominant trait and is characterized by late onset slowly 
progressive muscle weakness also involving the diaphragm, causing respiratory failure. 
Respiratory insufficiency may be the presenting symptom in some cases (27). Since the 
original report in 1990 several other groups have reported more families from UK (28, 29), 
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Finland, France, Germany and Argentina (27). The muscle pathology typically shows 
unspecific myopathy, rimmed vacuoles and cytoplasmic bodies positive for anti-myotilin and 
anti-alpha B-crystallin. Nicolao et al found linkage to 2q24-q31 (30) and considered titin 
(TTN) to be a strong candidate gene. Lange et al (31), found a heterozygous missense 
mutation in TTN. Later Palmio et al (27) investigated several unrelated families and found 
different missense mutations affecting the FN3 119 domain in A-band of titin. It remains to 
elucidate the functional effects of the mutations, but abnormal autophagy and dysregulation 
of protein turnover is hypothesized (27). 
 
Gene Protein    Disorder OMIM 
DES Desmin MFM1 601419 
CRYAB αB-crystallin MFM2 613869 
MYOT Myotilin MFM3 609200 
LDB3 
LIM domain-binding 
protein C3 (ZASP) 
MFM4 609452 
FLNC filamin C MFM5 609524 
BAG3 Bag3 MFM6 612954 
PLEC1 Plectin 




MFM 9 Hereditary myopathy with 
early respiratory failure (HMERF) 
603689 
Table 2. Examples of myofibrillar myopathies and their corresponding genes and proteins. 
1.1.2.5 Reducing body myopathy 
Reducing body myopathy (RBM, OMIM 300718) was first described in 1972 by Brooke and 
Neville (32). It is a rare myopathy belonging to the group of myofibrillar myopathies (see 
above) but with some distinguishing features, both clinically and genetically. RBM has a 
wide clinical spectrum ranging from early onset fatal disease to a mild disorder with onset in 
adulthood (33). Apart from muscle weakness and atrophy contractures and rigid spine also 
occurs (34). The hallmark of this disease is intracytoplasmic aggregates displaying strong 
reducing activity when stained with nitro-blue-tetrazolium (NBT), presumed to be due to 
reduction by sulphydryl groups. All reported cases were later shown to be caused by 
mutations in the four and a half LIM domain gene FHL1 on the X chromosome. The 
inheritance can be de novo, X-linked dominant and X-linked recessive. In inherited cases, due 
to the X-chromosomal location of the gene, males are often more severely affected than their 
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mothers or grandmothers (33). In contrast to the allelic, and somewhat phenotypically 
overlapping, disorders Emery-Dreifuss muscular dystrophy 6, myopathy with postural muscle 
atrophy and scapuloperoneal myopathy, patients with reducing body myopathy usually have 
mutations affecting the second LIM domain in the FHL1 protein encoded by exon 3 of the 
FHL1 gene. The allelic disorders have mutations affecting other domains, e.g. exon 5 to 8 in 
Emery Dreifuss muscular dystrophy type 6 (35). RBM due to FHL1 mutations should also be 
considered as a differential diagnosis in rigid spine syndrome (36). 
 
Figure 8. A. Immunostaining for FHL1-positive inclusions. B. Stain with nitro-blue-tetrazolium (NBT) showing 
strong reducing reactivity. Scale bars 100 µm. Reprinted with permission (37). 
1.1.2.6 Myopathy with vitamin E deficiency 
Deficiency of vitamin E is today a very uncommon cause of myopathy in the developed 
world. It is sometimes occurs in association with cholestasis and reduced uptake of vitamin E 
(38). Other reported symptoms of chronic deficiency of vitamin E are ataxia (39) and 
cardiomyopathy (40). Vitamin E deficiency does not cause isolated myopathy and the 
muscular symptoms are overshadowed by other neurological features. The histological 
features in vitamin E deficient induced myopathy include unspecific myopathic and 
neurogenic changes, but also accumulation of autofluorescent lipofuscin granules, like the 
autofluorescent inclusions seen in sarcoplasmic body myopathy (see below). There are some 
differences compared to the inclusions seen in sarcoplasmic body myopathy: the inclusions in 
vitamin E deficiency are PAS-positive, often localized just beneath the sarcolemma and emit 
yellow autofluorescence (38) while the inclusions in sarcoplasmic body myopathy are PAS-




A       B 
Figure 9. Muscle biopsy from unspecified muscle in patient with cholestasis and deficiency of vitamin E. A. 
Abundant basophilic inclusion (Htx stain), bar= 25 µM. B. Staining with acid phosphatase shows strong 
reaction, bar=50 µM. Reproduced with permission from (38). 
1.1.2.7 Pompe disease 
Pompe disease (OMIM 232300) is a recessively inherited disease belonging to the glycogen 
storage disorders (GSD2). It is caused by deficiency of the lysosomal enzyme acid alpha-
glucosidase, encoded by the GAA gene, that accounts for the small percentage of glycogen 
that is broken down in the lysosomes. In Sweden Pompe disease is very rare, 0.25/100 000 
persons (42), but in other countries the disorder is more common, e.g. in The Netherlands 
where the frequency is ten times higher, 2.5/100 000. This is most likely due to founder 
mutations in the population, 60% of patients carry either IVS1(-13T>G), 525delT or 
delexon18 (43). The disorder presents as a continuum of phenotypes ranging from debut in 
infancy to late onset cases. Infants presents at, or soon after, birth with severe hypotonia, 
hypertrophic cardiomyopathy, myopathy, respiratory insufficiency and macroglossia (44). In 
adult cases, late onset Pompe disease (LOPD), the symptoms resemble limb girdle muscle 
dystrophy with weakness predominantly in proximal muscles. Adult patients do not have 
cardiac involvement but usually pronounced involvement of respiratory muscles (45). 
Diagnosis is made by measurement of alfa-glucosidase in lymphocytes, fibroblasts, muscle 
tissue or in dry blood spots. Muscle biopsies are seldom performed nowadays but show 
general dystrophic features, round vacuoles and PAS-positive accumulation of glycogen. 
Since the morphological abnormalities are often very discreet in adult patients and the 
diagnosis can be missed if only biopsy is performed, measurement of enzyme activity is 
considered the gold standard for correct diagnosis. One frequent, but less known, finding in 
biopsies is a high prevalence of autophagic inclusions containing lipofuscin, this finding is 
more pronounced in severe cases (46). Treatment with recombinant enzyme is available for 
both infantile and adult onset patients. Enzyme replacement in infant patients seems to be 
more beneficial if started early (47), which has led to inclusion of enzyme testing as part of 
newborn screening in several countries. Taiwan was first (48) but the disease in now included 
in the Recommended uniform screening panel in the USA (49). The treatment effect is 
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excellent when survival is studied, but myopathy with atrophy, signal changes on muscle 
MRI and weakness of proximal muscles develops in spite of treatment (48). 
  
Figure 10.  A-C show PAS staining for glycogen accumulation from A. infantile, B. juvenile and C. adult onset 
Pompe disease with intense staining in the infant case but a very discrete glycogen accumulation in the adult 
case. D. An ultrastructurally swollen mitochondrion and lipofuscin accumulation, Asterix shows a lysosome 
with lipid accumulation. Reprinted with permission (46). 
1.1.2.8 Sarcoplasmic body myopathy 
Sarcoplasmic body myopathy (SBM) is an autosomal dominant myopathy first described in 
Sweden in the late 1970ies by Professor Edström and colleagues (41). They were studying 
microscopy sections from a muscle biopsy from a man with distal muscle weakness and saw 
black stains in the muscle, but thought it was caused by dirt on the microscopy lens. The 
inclusions, however, remained after cleaning the lens. The muscle tissue also had signs of 
myopathy with increased fibrous tissue, abnormal variation in fiber size and centrally located 
nuclei. The inclusions could be seen on every available immunohistochemical stain but did 
not absorb any staining themselves (Fig 11). Professor Edström went on to study the muscle 
specimen by electron microscopy (Fig 12) and concluded that the inclusions looked like, but 
were not identical to, lipofuscin granules (50). Lipofuscin is an insoluble yellow-brown 
pigment composed of oxidized lipids and proteins (51). It has been postulated that lipofuscin 
forms secondary to oxidative stress by radical oxygen species (ROS) generated by 
mitochondria (52). Lipofuscin inclusions in muscle can also be an unspecific sign of ageing 
thought to be the result of deficient autophagy and mitophagy rather than ROS-driven 
oxidative injury as mitochondrial ROS-production is similar in the elderly and the young 
(53). As mentioned above lipofuscin is also seen in other disease states affecting muscle 
tissue (46, 54, 55). In SBM there is also some resemblance to the inclusions seen in vitamin E 
deficiency (38) and the inclusions sometimes seen in Pompe disease (46) but to conclude the 
inclusions seen in sarcoplasmic body myopathy are distinctive from almost all inclusions 
seen in other myopathies. Three more patients, siblings of the index case, were located. The 
initial four patients were described in some detail in 1980 (41). The sarcoplasmic inclusions 
were then further characterized in 1981 (56). Professor Edström early on realized that the 
unique findings indicated that this was a new not previously described muscle dystrophy. 




Figure 11. Histochemical features of sarcoplasmic body myopathy. a. Anterior tibial muscle biopsy from an 
individual 10 years prior to the onset of symptoms, stained with hematoxylin and eosin, showing several rounded 
brown inclusions (arrows) (sarcoplasmic bodies) in the majority of myofibers and very small vacuoles in some 
myofibers (arrowhead in a). b, c. Biceps brachii from a Spanish patient, 15 years after disease onset. Note the 
presence of collections of sarcoplasmic bodies within the rimmed vacuoles. d, e. Sarcoplasmic bodies appear red 
on modified Gomori trichrome stain. e. In muscle biopsies with more advanced pathological lesions, large 
numbers of rimmed vacuoles are observed. f. No major architectural changes are seen on NADH reaction, apart 
from lack of oxidative activity at the site of vacuoles. Scale bar in a and f = 50 µm; scale bar in b, c and 
d = 20 µm. Adapted from (57) with permission 
   
A     B        C 
Figure 12. Electron micrographs of SBM muscle. In A. accumulation of sarcoplasmic bodies close to nuclei is 
shown. B. shows inclusions interspersed between myofibrils and along the sarcoplasma. C. is a high 
magnification of a sarcoplasmic body displaying its electron density and irregular shape. Unpublished images 
from personal collection. 
1.2 INHERITED ATAXIAS 
The term ataxia is derived from the Greek word for without order, disorder and illustrates the 
main ataxia symptoms; disturbance of gait, speech, eye movements and fine motor skills. 
Ataxia is a common symptom in neurological practice and ataxia of non-genetic origin can be 
secondary to e.g. alcohol abuse, trauma, multiple sclerosis, paramalignant causes or coeliac 
disease (58). These will not be further discussed here. 
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When investigating a patient with ataxia, one must bear in mind that some ataxias, not only 
acquired ones but also some of genetic origin, are treatable. The initial steps in the 
investigation should therefore aim at identifying those conditions. 
Primary coenzyme Q10 deficiency syndromes are caused by deficiencies in the co-enzyme 
Q10 (ubiquinone) biosynthetic pathway. The most common symptom of primary coenzyme 
Q10 deficiency is ataxia, but several other symptoms are often present. This group of 
syndromes are due to biallelic pathogenic mutations in the genes encoding the enzymes for 
coenzyme Q10 synthesis; PDSS1, PDSS2, COQ2, COQ4, COQ6, COQ7, COQ8A (ADCK3), 
COQ8B (ADCK4), and COQ9. Primary coenzyme Q10 deficiency is important to identify 
since many of the conditions respond to high doses of ubiquinone (59). Other treatment 
options may eventually be available, i.e. with drugs bypassing the enzymatic defect (60). 
Other treatable causes of ataxia are cerebrotendinous xanthomatosis, Refsum disease, 
Niemann Pick type C, Wilson disease and ataxia with vitamin E deficiency. 
The heterogenous group of hereditary ataxias are usually associated with cerebellar atrophy 
and can be inherited dominantly, recessively, X-linked or as a maternally inherited 
mitochondrial syndrome.  
Recessive ataxia syndromes most frequently have debut in childhood. Two examples are 
described briefly below. 
The most common recessive ataxia is Friedreich ataxia (FRDA) with disease onset between 
5-15 years of age and a frequency of 2/100 000. FRDA is almost exclusively caused by a 
homozygous GAA expansion in the FXN gene leading to a reduced expression of the gene 
product frataxin. Deficiency of frataxin leads to a progressive neurodegenerative disease 
which affects the cerebellum, spinal cord and the myelin sheaths of the peripheral nerves. The 
heart is involved in most cases causing hypertrophy, dilation and cardiac arrythmias. Frataxin 
has been shown to be involved in iron-sulphur cluster biogenesis and cause mitochondrial 
dysfunction, but the exact biochemical processes are poorly understood (61). 
Ataxia Telangiectasia presents in childhood with progressive cerebellar ataxia. Later a 
systemic disease with conjunctival telangiectasias, immune deficiency and malignancies 
develop. The disorder is caused by mutations in the ATM gene and the gene product, a 
phosphatidyl-3-kinase, is involved in phosphorylation of substrates involved in DNA repair 
and cell cycle control (62). 
1.2.1 Autosomal dominant cerebellar ataxia 
Autosomal dominant cerebellar ataxias (ADCAs) generally have later age of onset than 
recessive ataxias but overlap regarding debut age exists. ADCAs can in turn be categorized as 
spinocerebellar ataxias (SCA), currently numbered 1-48 (OMIM 2020-11-10), four different 




The most common and earliest identified SCA syndromes (SCAs), e.g. SCA1, SCA2, SCA3, 
SCA6, SCA7, SCA12, SCA17, and DRPLA, are all caused by heterozygous CAG 
trinucleotide expansions within the protein coding regions of the respective genes. The 
trinucleotide CAG encodes glutamine and thereby introduces a polyglutamine stretch that 
affects function of the respective gene products. The CAG repeat length is unstable and tends 
to increase in successive generations, a phenomenon known as anticipation. This often results 
in earlier age of onset and more severe disease in subsequent generations of the family. 
Molecular testing for the different SCAs is both sensitive and specific once the expansion is 
known. Genetic counselling is, however, not straightforward since disease prognosis cannot 
be concluded from repeat length only. There are, for instance reports of both mosaicism and 
the opposite of anticipation, contraction of the repeat length, that complicate the picture (64, 
65). Not all SCAs are caused by CAG expansions, SCA8 is caused by another trinucleotide 
repeat, CTG, and SCA10 is caused by the pentanucleotide repeat ATTCT. Several SCAs are 
caused by missense mutations, examples are SCA5 caused by mutations in the SPTBN2 gene 
encoding an isoform of β-spectrin with high expression in the cerebellum and SCA14 caused 
by mutations in PRKCG encoding protein kinase Cγ with highest expression in cerebral 
cortex and the spinal cord. SCAs caused by missense mutations are rarely associated with 
anticipation, with the possible exception of SCA5 (66). 
There are still several SCAs awaiting molecular characterization, for example SCA18 linked 
to 7q22-q32 and SCA20 linked to 11q12. SCA4 linked to 16q22.1 is another example of a 
unique SCA where the chromosomal region has been identified by linkage analysis, but the 
molecular cause is unknown. The first description of SCA4 was from a kindred of 
Scandinavian origin residing in Utah investigated by Flanigan et al in 1996 (67). The disorder 
was characterized by ataxia of late debut at a median age of 39.3 years. Apart from ataxia 
somatosensory axonal neuropathy was seen in all affected subjects. Linkage analysis was 
performed and resulted in a maximum LOD-score of 5.93 in a region of 6cM on chromosome 
16.  
The second description of SCA4 was of a five generation German pedigree published by 
Hellenbroich et al in 2003 (68). The affected individuals in this family had ataxia with debut 
at a median age of 38.3 years and all affected had axonal sensorimotor neuropathy. Linkage 
analysis showed, as in the Utah family, linkage to 16q22.1. Due to recombination events the 
group could narrow the chromosomal region to 3.69 cM. The group also screened the region 
for CAG/CTG repeats and found no expanded alleles and concluded that the disorder must be 
caused by another sort of expansion or by a different kind of mutation. 
Both the group from Utah and the German group found a tendency to anticipation with earlier 
disease onset and worsening of symptoms in successive generations, but this suspicion of 
anticipation could not be statistically proven due to small sample sizes. Characterization of a 




1.3 INHERITED METABOLIC DISORDERS 
The term inborn errors of metabolism was coined by Archibald 
Garrod in 1908, and later in a publication describing 
alkaptonuria and several other disorders (69). Inborn errors of 
metabolism comprise a huge number of diseases almost 
exclusively caused by defects in enzymes or transporters. Each 
individual disease is rare but since the number of disorders is so 
great the number of affected individuals is significant. 
Metabolic disorders can affect virtually every organ or tissue 
and impact on the nervous system is very common.  
Metabolism can be divided in 
different pathways, e.g. the 
synthesis or breakdown of a 
substance or molecule. In 
metabolic disorders pathways 
become disrupted, leading to 
either accumulation of substrate, 
toxic metabolites, deficiency of 
product or impaired energy production. 
1.3.1 The methionine cycle 
One very important biochemical pathway is the one carbon metabolism in the folate and 
methionine cycles (Fig 15). A correct function of these cycles is essential to provide methyl 
groups to a great number of methyl 
transferases, to produce cysteine and several 
other essential processes. There are many 
known defects of this pathway, both genetic 
and non-genetic. A common and well-known 
non-genetic cause of defective cycle function is 
deficiency of vitamin B12. This deficiency 
causes elevated homocysteine since methionine 
synthase requires B12 as a cofactor when a 
methyl group is donated from N-methyl 
tetrahydrofolate (N5-MTHF) to homocysteine to form 
methionine. Among the genetic causes the perhaps best 
known is homocystinuria, which is caused by biallelic mutations in the CBS gene encoding 
cystathionine β-synthetase. In this disorder both homocystein and methionine become 
elevated and cysteine synthesis is decreased. Five other genetic causes of elevated methionine 
are known; Mat I/III deficiency, Glycine-n-methyltransferase deficiency, S-
adenosylhomocysteine hydrolase deficiency, citrin deficiency and tyrosinemia type 1 (70). 
In the latter disorder the defective enzyme is not a part of the methionine or folate cycle. 
Figure 13. Sir Archibald Garrod 
Figure 15. Folate and methionine cycles 
Figure 14. Illustration of a metabolic block 
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Instead the defective enzyme fumarylacetoacetate hydrolase is involved in tyrosine 
metabolism and the defect causes accumulation of the toxic metabolite fumarylacetoacetate, 
which is a strong inhibitor of the MAT I/III enzyme. 
Paper IV is about the biochemical, genetic and clinical characterization of a seventh 
disorder causing hypermethioninemia. 
 
1.4 GENETIC DIAGNOSIS IN ACUTELY ILL INFANTS 
Inherited metabolic disorders with debut in early infancy are often treatable but difficult to 
diagnose (71).  The proportion of infants admitted to neonatal intensive care unit (NICU) due 
to metabolic disorders vary in different studies but tend to be under 1% (72) and the 
proportion with any genetic defect is unknown but thought to be high (73). Newborn 
screening is conducted in most Western countries to make a presymptomatic diagnosis but 
identifies only a subset of disorders. In Sweden, for example, 25 disorders (23 metabolic) of 
the over 1000 known metabolic disorders are included in the screening program (74), which 
is centralized to the Centre for Inherited Metabolic Diseases (CMMS) at Karolinska 
University Hospital. CMMS also performs biochemical and genetic follow-up of positive 
screening results. Occasionally a metabolic disorder presents before the results from the 
newborn screening is available, or even before the sample is taken (75). In metabolic 
disorders the typical symptoms are metabolic acidosis, lactic acidemia, hyperammonemia or 
severe hypotonia/floppy infant. In these cases, analysis of standard parameters as lactic acid, 
ammonia, blood gases, liver enzymes and CK can often give clues to the disease category but 
this is rarely enough for a specific diagnosis. More specialized methods, including urinary 
organic acids, plasma amino acids and plasma acyl carnitines, can sometimes lead to 
diagnosis if the baby is affected by an intoxication type metabolic disorder, but unspecific 
metabolite alterations due to feeding, medication, vitamin deficiencies and insufficient 
sample volumes often make diagnosis challenging (71). Specialized metabolic testing is time-
consuming and diagnostic delay can worsen patient outcomes, making an alternative or 





- To perform a detailed clinical characterization of sarcoplasmic body myopathy 
including neurophysiologic assement, muscle morphology and imaging 
- To molecularly define sarcoplasmic body myopathy by linkage analysis, sequencing 
of candidate genes and next generation sequencing after custom capture of the linked 
chromosomal region. To elucidate the pathogenetic process whereby the muscle 
phenotype in Sarcoplasmic body myopathy evolves 
- To perform a detailed clinical phenotyping in a large Swedish family with apparent 
SCA4 and to perform genetic investigations and study pathogenetic processes leading 
to damage in the cerebellum and periferal nerves  
- To perform a detailed biochemical and clinical assesment in a family with 
hypermethioninemia and to find the underlying cause of disease through massive 
parallell sequencing 
- To perform a proof-of-concept study to illustrate the value of adding rapid WGS to 





A broad range of diagnostic methods have been used in the different projects.  
Clinical investigations    Used in paper 
Rating scales;    III 
Hospital Anxiety and Depression Scale (HADS)  
Scale for the Assessment and Rating of Ataxia (SARA) 
Inventory of non-ataxia Symptoms (INAS)  
 
Biochemical analysis 
CSF analysis of markers of neurodegeneration,   III and IV 
monoamine metabolites, AdoMet and AdoHcy     
Nanoscale Secondary Ion Mass Spectrometry (NanoSIMS) II 
Specialized metabolite analysis   III, IV and V  
(amino acids, acyl carnitines, very long chain fatty acids etc.)   
Enzyme activity measurement of SAHH activity in fibroblasts IV 
Cloning, expression and determination of  IV 
activity in mutant ADK enzyme. 
 
Imaging 
MRI of muscle, heart or brain   I, II, III and IV 
Peripheral nerve magnetization transfer ratio and  III 
peripheral nerve diffusion tensor MRI  
[11C]Flumazenil-PET and    III 
[18F]FluoroDeoxyGlucose (FDG)-PET   
 
Pathology 
Neuropathological studies and immunohistochemistry of CNS III 
Muscle biopsy, morphological investigations  I, II, III and IV 
with light- and electron microscopy 
Fourier transform infrared microscopy (μFTIR)  II 
 
Neurophysiology and Physiology 
Electroneurography (ENeG), electromyography (EMG) I, II, III and IV 
Quantitative sensory test (QST), variability of RR-interval, III 
skin sudomotor response (SSR) and ambulatory 
polysomnography with Embletta 
Spirometry     I 
Cardiac ultrasound    I and II 
Electrocardiogram (ECG)    I and III 
 
Genetic investigations 
Polymerase chain reaction (PCR) and Sanger sequencing II, III and IV 
Whole exome/genome sequencing (WES/WGS)  IV and V 
Custom capture followed by massive parallel sequencing II and III 
Multipoint linkage analysis and haplotype analysis  II and III 





4 ETHICAL CONSIDERATIONS 
Below is a discussion of the ethical considerations that have been raised in the studies 
constituting this thesis. The ethical implications have been extensively discussed within the 
research group. In sarcoplasmic body myopathy, paper I and II, I alone have had most 
contacts with the research subjects. For autosomal dominant ataxia, paper III, we have been 
two investigators leading the project and had many discussions among ourselves and with our 
supervisors on how to conduct the research in an ethically correct manner. For the studies 
involving minors, paper IV and V, the situation is a bit different. These studies all involved 
children with severe recessive disorders and communication has exclusively been with the 
children’s guardians. All projects have been approved by the regional ethics committee.  
4.1 GENERAL REMARKS 
When performing genetic studies or testing in humans it is of paramount importance to 
adhere to consensus ethical guidelines (http://www.eurogentest.org/index.php?id=645, 
https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Practice-
Guidelines.aspx). 
4.2 SARCOPLASMIC BODY MYOPATHY 
All patients and unaffected carriers entering the studies reported in paper I and paper II have 
received written and oral information before signing the informed consent document. Early 
on we realized that inclusion bodies could be detected in muscle biopsies decades before the 
onset of clinical symptoms. This finding was evident long before linkage analysis enabled us 
to make the diagnosis with haplotype analysis or, even later, by direct sequencing of the 
mutated gene. 
When discussing the possible inclusion of a new individual in the studies we gave extensive 
information of what was known about the disease, it’s inheritance and it’s predicted course. 
We also offered the right for each person to remain unknowing of their disease status, 
meaning that we refrained from communicating the results from various investigations such 
as muscle biopsy, linkage analysis and genetic investigations. Minors, who are all 
asymptomatic, were told they had to wait until they reach legal age (18 years) before entering 
the study, parents were not allowed to enter their children.  
Several of the patients opted for not knowing their disease status. These individuals were kept 
uninformed, either until they developed symptoms or until they changed their minds and 
wanted to be informed if they were affected or not. In case a study subject wished to be 
informed of his or her disease status we used an approach similar to what is done in genetic 
counseling for Huntington disease (76) and other severe late onset dominant diseases. 
For pre-symptomatic persons wishing to either know the results of previous investigations or 
to have a presymptomatic test, a personal visit was scheduled. On this visit, which was almost 
exclusively hosted by me, extensive disease information and the current status of the research 
project were conveyed. We then proceeded to discuss why the individual wanted testing and 
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whether knowledge of disease status would do any good at all in their current life situation. In 
several instances the testing or conveying of previously known information was wanted 
because the individuals were planning to have children and did not wish to propagate the 
disease to following generations. After exploring the strength of motivation for testing a 
description of the testing procedure was given. The visit then continued with a discussion 
what the result would mean to the individual as both a positive and a negative result could 
have impact of the person’s well-being. According to my experiences a positive result may 
lead to a life crisis and a negative result may elicit a reaction similar to “survivors’ guilt”. 
After leaving room for questions the visit then ended without making any decision to test or 
not but instead the individual was told to think the decision through for a minimum of one 
week’s time. 
The follow up was usually made by a phone call. If the individual still wanted 
testing/knowledge of results a new visit was booked to communicate the results. No results 
have been communicated by phone and the persons receiving the results of testing were 
encouraged to be accompanied by someone to support them. When the visit for result 
communication took place it always started with me asking if they still wanted to be informed 
of the result, as this is something that can never be undone.  
The results were then revealed as plainly as possible. Strong emotional reactions were the 
rule, whether the result was positive or negative. Often renewed disease information was 
necessary. For persons with especially strong reactions counselors connected to the 
neuromuscular team were available and some of the patients underwent crisis therapy. 
Regardless of the result follow-up questions from the tested person were common and the 
persons therefore received both my email address and my telephone number and were told 
not to hesitate to take contact. 
Prenatal diagnosis has been performed in several instances. One couple where the disease 
status was known in one of the parents underwent preimplantation genetic testing (PGT), 
sometimes referred to as preimplantatory genetic diagnosis (PGD). By this procedure the first 
step is to take a semen specimen from the to-be father and to collect oocytes from the to-be 
mother after ovarian stimulation. An in-vitro fertilization is then made, and embryos are 
investigated for the disease-causing mutation followed by implantation of an unaffected 
embryo. In other instances, where the person at risk did not want to know the disease status, 
we chose a different approach through a naturally induced pregnancy followed by a chorion 
villus biopsy. That biopsy was then used for grand parental exclusion test using the alleles 
from the subject’s grandparent to exclude that the disease allele had been inherited to the 
fetus without revealing disease status to the future parent. The same procedure can be used in 
PGT if the couple wishes to have that procedure.  
4.3 SPINOCEREBELLAR ATAXIA TYPE 4 
In this project all subjects receive extensive oral and written information regarding the 
disease we study, including the different investigations we plan to perform and the genetic 
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investigations that are underway. Study subjects are then invited to enter the study and sign 
the consent forms. For a long time, we lacked pre-symptomatic testing for this disorder and 
didn’t have access to pre-symptomatic biomarkers. A possibility may be to use pre-
symptomatic signs of autonomic disturbances. Now the situation is different when we have 
been able to establish a haplotype with strong linkage to the disease locus enabling pre-
symptomatic testing. This has not yet been requested from any of the family members, but 
there will most likely arise such requests. We will, when the issue comes up, adopt the same 
strategy as when testing for sarcoplasmic body myopathy. 
4.4 ADENOSINE KINASE DEFICIENCY 
The two Swedish children included in this study were both severely ill with an intellectual 
involvement that made direct communication with them impossible. One sibling was 
deceased. Instead the parents were informed about the ongoing research from their 
pediatrician and from myself and my supervisor. When whole exome sequencing became 
available, we travelled to Dalarna North of Stockholm to meet the surviving older male 
sibling, the parents and the responsible pediatrician. This made a more comprehensive 
discussion possible. I also had an appointment for genetic counseling with the healthy brother 
and his spouse. 
4.5 RAPID PULSED WHOLE GENOME SEQUENCING 
In this project the parents of the investigated infants were informed about the project before 
signing informed consent. After investigations they were also informed about the results. In 
the case of the child included prospectively, in whom we could not find a genetic cause of the 
condition, a thorough metabolic workup was performed that did not reveal any indication of a 
metabolic disorder. This child had a lactic acidosis of unknown cause that subsided 





5.1 SARCOPLASMIC BODY MYOPATHY, SBM 
I became involved in this project 1999 when I had recently started my training to become a 
neurology specialist at Karolinska University Hospital. The early work in the SBM family of 
professor Edström et al had been followed up by a linkage analysis that showed linkage to 
chromosome 22 (unpublished).  
I started extended investigations of additional members of the family in year 2000, most of 
them descendants of the initial affected members from the publications of Edström et al (41, 
56).  
5.1.1 Paper I 
 
When I started out to further define the phenotype of sarcoplasmic body myopathy (SBM) we 
realized that the highly unusual inclusions in muscle tissue were pathognomonic of the 
disease leading to the hypothesis that they might be present presymptomatically. I then 
contacted the different members of the family and offered all at-risk persons inclusion in the 
study. In this process it became evident that individual II:2 and his descendants were related 
to the rest of the family due to a common ancestor (I:2) interlinking the two branches, see 
pedigree (Fig 16). All newly identified family members were offered to take part in the study, 
without being informed of the results if they wished. Nine persons accepted to be included. 
Some declined, two since they did not want to undergo the investigations, a third thought the 
research was futile and the rest lived in faraway locations and declined for logistical reasons.  
The research protocol included a detailed history and manual muscle testing (MMT) (77) of 
all relevant muscle groups. Also included in the protocol were laboratory testing for CK, 
alpha-tocopherol, muscle biopsies of the anterior tibial muscle or vastus lateralis and 
neurophysiology testing including electromyography (EMG), electroneurography (ENeG) 
and quantitative sensory testing (QST). To visualize the distribution of muscle affection 
muscle MRI was performed in three individuals, two symptomatic and one pre-symptomatic. 
Spirometry was included to investigate whether affected respiration could be detected at early 
disease stages. At the time no patients had complained of or died from heart affection. In 
order to address this issue electrocardiogram (ECG) and cardiac ultrasound were included in 
the protocol. 
In this study I did all clinical investigations myself and performed the neurophysiology 
examinations (under supervision from an experienced neurophysiologist). I also handled all 
communication with the family, constructed the pedigree and wrote the first draft of paper I. 






Figure 16. Pedigree of Swedish family with sarcoplasmic body myopathy showing a common ancestor in 
individual I:2. Individuals included in paper I are marked with arrows. Affected individuals are defined as those 
who have both presence of inclusions and elevated creatinine kinase (CK). Individuals not wishing to be 
informed of their disease status are excluded. 
 
An early symptom noted in the previous studies was weakness of the thenar muscles between 
the thumb and the index finger. In paper I, I show that some of the individuals have proximal 
weakness with difficulty rising from chairs and walking stairs as initial complaint. An initial 
complaint can also be symptoms only at exertion, as one patient (IV:4) complained of muscle 
fatigue without associated weakness. From interviews and clinical investigations, I could 
conclude that, although two subjects had distal hand weakness (III:5 and III:9), proximal 
weakness seemed to be a far more common first complaint than distal weakness. The most 
affected muscle groups were the hip flexors.  
Muscle biopsies were obtained from all nine individuals and showed inclusions in six (IV:2, 
IV:4, III:7, III:9, III:14 and III:15) (Fig 17, Table 3). It became evident that the sarcoplasmic 
inclusions could indeed be seen before overt clinical symptoms appeared, as seen in three 
patients (IV:2, IV:4 and III:15). In individuals with clear disease symptoms there were, in 
addition to inclusions, signs of unspecific myopathy with increased number of centralized 
nuclei, variation in fiber size and fibrosis. In the pre-symptomatic individuals muscle 
morphology was completely normal except for the sarcoplasmic inclusions.  
 
A       B           C 
Figure 17. Muscle biopsy sections from patients affected by SBM. A Hematoxylin eosin staining from patient 
III:9 in pedigree (Fig 16), taken approximately 10 years after debut of symptoms. There are unspecific 
dystrophic features with increased centralized nuclei, variability in fiber dimension and increased connective 
tissue. Sarcoplasmic inclusions can be seen scattered in sarcoplasm (arrows). B Gomori trichrome stain from 
a biopsy taken pre-symptomatically from individual III:15 showing an abundance of sarcoplasmic inclusions 
in otherwise normal muscle. C ATP:ase staining showing type 1 fibers (white), type 2B fibers (grey) and type 
2A fibers (black). Sarcoplasmic inclusions are seen in all fiber types. 
 
26 
In the laboratory investigations all affected individuals had slightly increased CK, varying 
between 1.5-4 times the normal level. One unaffected female individual, IV:3, had slightly 
increased CK of unknown reason. In order to try to exclude deficiency of vitamin E we 
measured alpha-tocopherol in blood, which was normal in all subjects. 
Because of the presumed debut with distal muscle weakness neurophysiologic studies were 
performed that ruled out neuropathy as contributing to the distal weakness. From the 
neurophysiologic study we learned that myopathic signals could be detected pre-
symptomatically only in the iliopsoas muscle in two subjects (IV:2 and IV:4). There were no 
consistent signs of neuropathy except in one individual who had concomitant hepatitis C. 
MRI of both proximal and distal muscles of the upper and lower extremities were obtained 
from three individuals (Fig 18). 
   
A    B 
Figure 18. A T1 image from the thigh of Swedish individual III:15 four years after onset of symptoms. Vastus 
lateralis and rectus femoris are not much affected but signs of degeneration can be seen in hip adductors and 
knee flexors. B T1 weighted image of individual III:5 19 years after onset. Note the relative sparing of gracilis 
and sartorius muscles in the otherwise generalized fatty atrophied musculature. Unpublished images from 
personal collection. 
Cardiac ultrasound, ECG and spirometry showed no signs of early affection of either the 











Table 3 summarizes the clinical and laboratory findings of the nine individuals investigated 
for paper I. 
 
Table 3 with an overview of characteristics of the nine individuals included in paper I. Four of the affected 
individuals had complaints of muscle symptoms, two of the affected were pre-symptomatic and three were non-
affected. In one of the presymptomatic cases EMG changes were detectable only in the iliopsoas muscle. All the 
affected and one of the unaffected had increased CK at the time of the study. The reason for the increased CK in 
the unaffected is unknown. The hallmark of the disease, the characteristic sarcoplasmic inclusions, could be seen 
in all affected subjects, presymptomatically in two subjects. MMT, manual muscle testing; CK, creatine kinase; 
UNL, upper normal limit; EMG, electromyography; ENeG, electroneurography; QST, quantitative sensibility 
testing. * Subject III:7 was investigated at another center. † In these subjects the biopsied muscles, tibialis 
anterior or vastus lateralis, were of normal strength and morphologically normal except for numerous 
sarcoplasmic inclusions. Numbers correspond to generation and subject number in pedigree in Fig 16. 
 
5.1.2 Paper II 
In parallel with the clinical studies and as more individuals in the family became affected or 
were otherwise located, an extended linkage analysis focusing on chromosome 22 was 
performed by our group. This resulted in the highest LOD-score, 5.8, in a region on 
chromosome 22 containing approximately 100 genes (Fig 19). 
The myoglobin gene (MB) was in this region but was initially not considered a primary 
candidate gene since the mechanism of disease seemed to be oxidative damage. Instead we 
sequenced a few candidate genes thought to be involved in redox biology, e.g. TXNRD2, 
encoding mitochondrial thioreoxin reductase 2, without finding any disease-causing variants. 
We also found accumulation of intermediate filaments with an estimated weight of 55 kD 
seen in electron microscopy. An early hypothesis was that the filaments, and possibly the 
inclusions, were aggregated defective desmin filaments. Desmin filaments have a similar 
molecular weight (53 kD) as the identified filaments, but sequence analysis of the DES gene 





Figure 19. Multipoint LOD (logarithm of the odds) score plot of the linkage region identified on chromosome 22 
for the Swedish SBM family. A LOD-score above 3 is usually considered significant and represents roughly a 
1000 to one odds that the disease and the marker are linked. In this case the chance is 105.8, translating into an 
odds of 600 000 to one that the disease gene and the linkage region are linked in the family.  
The years went by and technology advanced. When next-generation sequencing became 
available we designed a custom capture of the entire linked region and flanking genomic 
sequences, in total comprising over 400 genes. This was performed in eight family members, 
6 affected and 2 unaffected. After bioinformatic analysis the top candidate gene was MB, 
where the variant c.292C>T (p.His98Tyr) was found in all affected individuals but not in the 
two unaffected persons.  
The MB gene product, myoglobin, was the first protein to have its 3D structure described by 
X-ray crystallography (78). Since mice where the equivalent gene was knocked out showed 
no obvious muscular phenotype (79), we realized that it would be a difficult task to prove that 
the mutation had functional effects. Attempts to use morpholino antisense oligonucleotides 
(80) in zebra fish were unsuccessful. The fish behaved normally, and no muscle inclusions 
developed, possibly because the effect of morpholino treatment was transient or the time was 
too short to develop muscle inclusions. However, our favored hypothesized mechanism was a 
slowly developing pathology due to a toxic gain rather than loss of function. We were in the 
process of trying to study the oxygen dissociation curve in homogenized muscle specimens 
when I got contacted by Professor Nigel Laing in Perth, Australia, who in turn collaborated 
with Professor Montse Olivé in Barcelona, Spain. They were investigating patients from two 
families, from Mallorca and mainland Spain, who had similar phenotypes and morphological 
findings. The Australian group performed genetic investigations with a different approach 
compared to us. Instead of linkage analysis followed by custom capture this group used 
whole exome sequencing from three affected members of the two families followed by 
filtering for genes encoding proteins with high expression in skeletal muscle from the 
FANTOM5 project (81). This strategy resulted in finding the same mutation in MB in both 
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families, c.292C>T (p.His98Tyr), which is identical to the mutation found in the Swedish 
family.  
Together we decided to prepare a joint publication. My part in this work was to design the 
study in collaboration with the Spanish-Australian group. I also coordinated all contacts 
between the Swedish group and other collaborators. My close and long-standing contact with 
the family proved to be crucial since new muscle samples were needed for different 
functional studies and availability of patients from the other families was very limited. I also 
provided images from light and electron microscopy, MRI images, clinical and laboratory 
data, linkage analysis and data from custom capture and MPS. The Swedish group did the 
haplotype analysis and Sanger sequencing from the other families and my responsibility was 
to coordinate shipping and registration of samples and results. The biochemical and physical 
characterization of the MB mutation was performed in collaboration with groups in Italy, 
Spain and Austria. I also wrote drafts of the manuscript. 
Later three more families, two from France and one from the Netherlands, were identified. 
The functional validation experiments were based on a hypothesis of a toxic gain of function 
as a result of the mutation. The rationale for this was that myoglobin knockout mice did not 
develop muscle weakness and survived into adulthood displaying several adaptations to the 
lack of myoglobin without developing any inclusions. 
Nanoscale secondary ion mass spectrometry (NanoSIMS) analysis of the sarcoplasmic 
inclusions showed increased signals for sulphur and iron, signs of oxidative damage and 
myoglobin degradation with possible lysosomal iron accumulation (82, 83). The high sulphur 
and the somewhat increased iron content were known before. When Edström et al in (56) 
studied X-ray spectra combined with electron microscopy in scanning mode in different 





A         B 
Figure 20. Comparison of findings from (56) published 1981 and paper II published 2019. A X-ray spectra from 
sarcoplasmic bodies (c and f) show high sulphur peaks (arrows). The sulphur peak is also demonstrated in the 
myofibrillar region containing sarcoplasmic bodies (d) and in cell nuclei (e). The spectrum from a sarcoplasmic 
body shows that, in addition to high Sulphur, there is also a small iron peak (f). B parts of fig 5 from paper II. 
Electron micrographs a-d show sarcoplasmic bodies of different appearance; under the sarcolemma (a), enclosed 
by a membrane (b), near vesicles (c), and in cardiac muscle (d). Micrographs e-g corresponds to the NanoSIMS 
images h-j. Blue indicates Sulphur (32S), red phosphorus (31P), and green (56Fe), respectively. 
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Further analysis with Fourier transform infrared microscopy (μFTIR) showed signs of lipid 
peroxidation, further strengthening the findings of oxidative damage. 
Biochemical studies directed at the myoglobin binding of heme, the O2 -binding properties 
and the oxidative state of iron were also conducted. This showed that the dissociation 
constant for the heme prosthetic group in mutant myoglobin was significantly higher 
compared to wildtype myoglobin. The diffusion of heme to different cellular compartments 
may result in ROS-mediated oxidative damage (84). Next, we studied the oxygen-binding 
properties and found that mutated myoglobin had a significantly reduced affinity for oxygen 
compared to wildtype, which might affect the ability for mutant myoglobin to store oxygen. 
Finally, the oxidative state of iron was studied by measuring superoxide levels in HEK293FT 
cells expressing wild type (WT) and mutant myoglobin. The superoxide levels were slightly 
higher in cells expressing mutant myoglobin compared to WT. This could be an indication of 
increased ROS generation caused by free heme.   
 
Table 4. K-H, the dissociation constant for heme at pH 7 and 5. Mutant myoglobin has 5 times higher K-H, most 
likely caused by decreased interaction between heme propionate-7 and the mutant Tyr residue compared to the 
interaction between heme propionate-7 and the His residue in WT myoglobin. At pH 5 the K-H is increased for 
both WT and mutant myoglobin but the difference in K-H between WT and mutant myoglobin decreases, 
probably due to increased protonation of heme propionates resulting in reduced interaction with myoglobin. At 
pH 7 the increased tendency for heme to dissociate could cause heme mediated ROS activation resulting in 
oxidative damage to muscle cells. E°’, the reduction potential of myoglobin, shows slightly lower values for 
mutant myoglobin that would thermodynamically favor auto-oxidation to MetMB even if  kox, the 




Figure 21. Kinetics of dioxygen binding to wild-type human myoglobin and the variant His98Tyr. 
a) Spectral changes upon reaction of 1 µM ferrous 
wild type hMb (black line) with 10 µM O2. The final 
spectrum represents oxymyoglobin (red line, 68 ms 
after mixing). Gray lines represent spectra obtained at 
0.68, 2.72, 4.08, 6.12, 8.84, 12.24, 34.00, and 51.00 ms 
after mixing. The inset depicts experimental time traces 
at 418 nm of wild-type hMb (solid black line) and 
p.His98Tyr MB (dashed black line) mixed with 
10 µM O2 and corresponding single-exponential fits 
(solid red line, wild-type MB; dashed red line, 
His98Tyr MB). 
 
b) Linear dependence of kobs values from the 
O2 concentration for wild-type MB (gray circles, solid 











c) Basal intracellular superoxide levels in HEK293FT 
cells expressing WT or mutant MB-EGFP. Data 
presented as individual data points and the 
mean ± SEM, numbers in parenthesis represent n. 
*indicates p = 0.007 (Mann–Whitney test, two-tailed) 
 
 
One interesting finding is that the same mutation was recurrent in all six families. To rule out 
that the families were distantly related to each other haplotype analysis on 3 Mbp adjacent to 
the MB gene was performed showing that the six families belonged to at least three different 
haplotypes (Table 5). 
 
Table 5. Microsatellite markers on 3 Mbp surrounding the MB gene in the six families. The Swedish family 3 
differs in microsatellite marker from families 1-2 and 4-6 indicating no common ancestor and that the 
mutation has developed on different genetic backgrounds. In family 5 the three siblings, one affected and two 
unaffected, have identical microsatellite markers raising the possibility of a de novo mutation. 
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The finding of a possible de novo mutation in family 5 could imply that the mutation has 
arisen in a mutational hotspot and raises the possibility that more families with the disease are 
hitherto unrecognized. Unfortunately, the parents in family 5 were diseased and not available 
for genetic analysis, meaning that we could not prove that the mutation was de novo. 
5.2 SPINOCEREBELLAR ATAXIA 
In the year 1999 I first met a male patient born 1936. He was excluded from military service 
at age 20 due to areflexia, but debut of overt ataxia was at 42 years of age. At the time of 
investigations, he had both profound ataxia and symptoms of polyneuropathy. Apart from this 
one of the patient’s main complaints was dizziness upon standing and attacks of profuse 
sweating. He also had erectile dysfunction since many years. A simple bed-side tilt test 
showed a blood pressure of 185/90 when lying down that dropped to 85/65 upon standing up.  
The index case reported that several relatives, including his mother, had ataxia symptoms. 
The initial workup included MRI of the brain and spinal cord, neurophysiologic 
investigations including autonomic function testing and screening for common genetic causes 
of ataxia. In the workup analysis of very long chain fatty acids (VLCFA) to rule out 
adrenomyeloneuropathy, fat biopsy to investigate for amyloid accumulation and muscle 
biopsy was also included. 
MRI of the brain in 1999 showed both supra- and infratentorial atrophy, most pronounced in 
the cerebellum where widened sulci were seen. MRI of the spinal cord was essentially normal 
except for slight degenerative changes. 
Neurography (ENeG) showed a predominant axonal neuropathy with low amplitudes and 
only moderately reduced conduction velocities. EMG showed predominantly neurogenic 
abnormalities with high amplitude compound motor unit potentials. Quantitative sensibility 
testing (QST) showed complete absence of thresholds for all modalities, cold, heat and 
vibration, in the feet and elevated thresholds for vibration in the hands. Autonomic testing 
revealed profound affection of both the sympathetic and parasympathetic systems. Tilt test 
showed a significant drop in blood pressure when standing up. RR-variability, the change in 
heart rhythm in response to breathing, was only slightly decreased 1,017 (ref >1,098), but 
when the rate of change in heart rhythm was analyzed,  the accelerations, the measurement 
became more significant. AI (acceleration index) was 1,2 (ref>4,5). 
Genetic screening for common ataxia syndromes that included analysis for SCA1, 2, 3, 6 and 
7, DPRLA, Friedreich ataxia and CMT1A was negative. Measurement of VLCFA was normal 
and a biopsy from abdominal fat showed no amyloid accumulation. Muscle biopsy showed 
neurogenic abnormalities with increased fiber type grouping and groups of atrophic fibers, 
but no signs of myopathy or mitochondrial dysfunction. 
At this point I concluded that the patient must have a rare form of autosomal dominant ataxia 
and involved Martin Paucar, a colleague working subspecialized in ataxias. We hypothesized 
that the family was affected by SCA4. 
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5.2.1 Paper III 
After designing the study and approval from the ethics committee we contacted relatives of 
the index case. Early on we met a second large family affected by ataxia, polyneuropathy and 
dysautonomia. This family was also included in the study. 
In family 1 a total of seven affected persons were available for clinical investigations, for 
another six persons medical records were available, for an additional three subjects, history 
from relatives could confirm ataxia. In family 2 two individuals were available. The disease 
is inherited in an autosomal dominant fashion with equal affection of both genders. All 
affected subjects had ataxia, polyneuropathy and all, with the possible exception of one 
subject in family 2, had autonomic symptoms (Tables 6 and 7). 
 
 
      A               B 
Figure 22. Pedigrees of Swedish family 1 and 2 with spinocerebellar ataxia. A. Swedish family 1. The index case 
in family 1 is number IV:3. This part of study includes 16 affected patients, 7 have been examined by us. Disease 
status of the remainder was corroborated by review of medical records and/or history. B Pedigree of family 2 
with spinocerebellar ataxia. The index case is number IV:4, only this patient and the parent, III:4, have been 
available for investigation. The remaining subjects have been reviewed by medical records and/or by history. 
Age of onset was 48.2 years in family 1 and 40 years in family 2. The clinical investigation 
indicated a combination of cerebellar and sensory ataxia in line with previous studies. 
Autonomic symptoms were almost universal in family 1 and present in the oldest patient in 
family 2 (III:4). Pedigrees of family 1 and 2 can be seen in Fig 22, clinical features are 
summarized in Table 6 and autonomic features are summarized in Table 7. 
Neurophysiological investigations showed a predominantly axonal neuropathy in all 
investigated patients as shown in Table 6. All investigated patients also had small fiber 
impairment that was most prominent when heat thresholds were measured. Autonomic 
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dysfunction demonstrated in tilt test and pathological RR-variability was evident in all tested 
subjects. In Table 7 subject IV:4 is annotated as not having overt autonomic dysfunction 
since sympathetic skin response (SSR) was normal. 
Four patients from family 1 who underwent MRI of the brain and spinal cord displayed 
significant atrophy of the vermis, pons, medulla and spinal cord. In family 2 subject IV:4 had 
atrophy of both vermis and pons, the spinal cord was not significantly atrophied. In individual 
III:2 atrophy of vermis was reported on CT-scan only. Figure 23 shows typical findings in 
brain and spinal cord MRI. 
  
A                          B 
Figure 23. A sagittal T1-weighted brain image in patient IV:1 from family 1 showing significant atrophy of the 
vermis and pons. Segmentation of mesencephalon, pons and medulla oblongata is illustrated with orange lines. B 
sagittal T2-weighted image of the upper spinal cord in patient IV:6 in family 1. Spinal atrophy is evident. SUP: 
Superior; ANT: Anterior; POST: Posterior; INF: Inferior.  
Neuropathology was performed in two individuals, IV:3 from family 1 and III:2 from family 
2. Histopathological investigations showed thinning of the granular layer of cerebellum and 
loss of Purkinje cells in both subjects (Fig 24). Investigation of the spinal cord showed loss of 
motor neurons in the anterior horn, also in both subjects. Investigation of the sural nerve 
showed unspecific and moderate loss of myelinated small fibers in three patients, by nerve 
biopsy in subject IV:1 from family 1 and by post mortem examination in IV:3 from family 1 




A             B 
Figure 24. A. Patient III:3 from family 1. B. Healthy control. Reduced number of calretinin positive cells in the 

























































































































































































































































































Table 7. Dysautonomic features in SCA4. ESS: Epsworth Sleepiness Scale; OSA: obstructive sleep apnea; RR 
interval variation on an electrocardiogram; SSR: sympathetic skin response. a This patient was diagnosed with 
severe  irritable bowel syndrome early in life. N=No, Y=yes, NA=not assessed. 
Multipoint linkage analysis was performed in family 1 using the markers D16S3031, 
D16S3019, D16S397 D16S3067, D16S3141, D16S496, D16S3085, D16S3107, D16S421, 
D16S3086, D16S3095, D16S3624, D16S3059, D16S512, D16S3018, D16S516and 
D16S402. This confirmed linkage to chromosome16q22.1 with a maximum LOD score of 
3.7 (Fig 25). The linkage peak was located in a 3.69 cM region between markers D16S3019 
and D16S512. The index case from family 2 shared the haplotype found in family 1 in the 
candidate region.  
The whole linked region and surrounding genetic regions (chr16: 53633817-76593135, 
GRCh37) was custom captured and sequenced in six affected and four unaffected members 
from family1 by using a custom designed capture kit (NimbleGen SeqCap EZ Choice 
Library). No clear pathogenic variant could be identified that segregated with the disease. 
However, based on the sequence data, a refined haplotype could be established, reducing the 
linked region to 23 Mb (flanked by D16S415 and D16S515).  
 
Figure 25. Multipoint linkage analysis confirmed linkage with a maximum LOD score of 3.7 on chromosome 
































5.3 ADENOSINE KINASE DEFICIENCY 
5.3.1 PAPER IV 
When we first started to use whole exome sequencing for identification of disease-causing 
genes, we turned to our old, unsolved cases. As the first family, we decided to study a pair of 
siblings who had increased levels of plasma methionine that could not be explained by known 
monogenic disorders.  
The first affected child, a boy born 1987, exhibited failure to thrive, elevated liver enzymes 
and conjugated hyperbilirubinemia at 3-4 weeks of age. His sister, born 1996, had an almost 
identical disease course as her brother. The siblings come from a reportedly non-
consanguineous family in Dalarna. In the family was also a healthy older brother born 1985. 
At age 3-4 months there was an obvious delay in psychomotor development. At one year of 
age both siblings had macrocephalus with frontal bossing and debut of epilepsy with both 
generalized tonic-clonic and partial seizures before age 3. The first year of life metabolic 
screening with organic acids in urine and amino acids in plasma were unremarkable and the 
bilirubin levels normalized. The liver enzymes, however, remained elevated and there was 
also a slight increase in serum creatinine kinase (CK) of 10 µkat/L (ref <3.5). The 
combination of symptoms involving both liver, muscle and CNS raised the suspicion of a 
mitochondrial disorder, but mitochondrial biochemical and morphological investigations 
from a muscle biopsy were normal in one of the siblings, the boy. Liver biopsy was 
performed showing liver steatosis and fibrosis in porta zones. At eight years of age both 
siblings had severe intellectual disability with autistic features. They also developed reduced 
vision with atrophy of the optic nerves. The girl died at age 10 of a suspected epileptic seizure 
during sleep. The older brother had, at eleven years of age, a general muscle hypotrophy, 
scoliosis, kyphosis and shortened Achilles tendons. MRI of the brain showed atrophy of both 
white and grey matter in the brother but was essentially normal in the sister at age 14 months.  
Both siblings had increased levels of plasma methionine and p-AdoMet (Table 8) pointing to 
a disrupted methionine cycle (Fig 26). The metabolite pattern suggested that the biochemical 
block was in the conversion of AdoHcy to homocysteine. Previously six genetic causes of 
elevated methionine had been described (70). The pattern of metabolite elevations in our 
patients could point to defective S-adenosyl-homocysteine hydrolase (SAHH) activity. 
After measurement of S-adenosyl-homocysteine hydrolase activity and sequencing of 
AHCY, the gene encoding this enzyme without finding any abnormalities, we concluded 









455 886 15-35 
P-homocysteine, 
µmol/L 
9.7 15 5-15 
P-AdoMet, nmol/L 677 496 55-116 
P-AdoHcy, nmol/L 122 102 9-45 
U-adenosine, 
µmol/mol creatinine 
7.1 9.85 <1 
Table 8. Biochemical investigations showed a pronounced elevation of methionine in plasma and indications 
of a functional block in the conversion of S-adenosyl-homocysteine (AdoHcy) to homocysteine (Hcy) in both 
siblings. 
The family was selected for whole exome sequencing, making this the first Swedish family 
to undergo such an investigation. 
After exome capture, sequencing and bioinformatic filtering a homozygous mutation, 
c.902C>A (p.Ala301Glu), was found in the ADK gene as described in paper I. This finding 




Figure 26. The methionine cycle 
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 Sibling 1 Sibling 2 Siblings 1 and 2 
 Dom Rec Hom Dom Rec Hom Dom Rec Hom 
NS/SS/I 4539 2789 2103 4452 2782 2111 3750 2270 1639 
Not in dbSNP131 424 62 26 422 49 21 213 28 13 
Predicted to be 
damaging 
204 17 10 195 17 8 100 10 5 
Table 9. The number of candidate genes resulting from bioinformatic data analysis in the affected pair of 
siblings in the Swedish family during different modes of filtering. Filtering against databases of known variants 
(dbSNP 131) and application of the recessive model for genes present in both siblings reduced the number of 
genes more than 150-fold in all cases and almost 350-fold for the homozygous model. Damage prediction from 
PolyPhen 2 further reduced the gene count to a total of ten and five genes that overlapped between the two 
siblings under the recessive and the homozygous models, respectively. The ADK gene was present in the final 
list of five genes. Abbreviations are as follows: Dom, ≥ 1 heterozygous or homozygous variant; Rec, ≥ 1 
homozygous or ≥ 2 heterozygous variants; Hom, ≥ 1 homozygous variant; NS, nonsynonymous variant; SS, 
splice-site variant; I, coding indel. 
In collaboration with other groups, four additional children from two families were 
identified. All subjects had similar biochemical and clinical phenotypes including frontal 
bossing and mutations in the ADK gene. 
A defective phosphorylation of adenosine to adenosyl-monophosphate (AMP) would be 
expected to also result in elevated adenosine. Therefore, we validated the functional 
significance of the genetic defect by confirming elevated urinary excretion of adenosine in 
the Swedish cases. We also demonstrated reduced activities of recombinant adenosine 
kinase enzymes carrying the different patient-derived mutations. 
  
 
Figure 27. Adenosine Kinase Activity from 
recombinant Wild-Type and mutant enzymes. 
Recombinant forms of wild-type ADK and ADK 
containing each of the mutations detected in 
individuals with ADK deficiency were expressed 
in E. coli, purified, and tested for their capacity 
to phosphorylate adenosine. The graph shows 
the mean value + 1 standard deviation of three 
independent measurements carried out with 
5 μM adenosine. All mutants displayed 
significantly impaired activity in comparison to 
the wild-type enzyme (two-tailed Student's t 
test). N.D. denotes not detectable; WT denotes 
wild-type. p.Ala301Glu are from Swedish 
patients, p.Asp218Ala and p.Gly13Glu are from 





5.4 RAPID PULSED WHOLE GENOME SEQUENCING 
5.4.1 PAPER V 
Massive parallel DNA sequencing provides a novel diagnostic opportunity, provided that the 
technology is adapted to healthcare standards and is customized to the specific clinical 
situation. Science for Life Laboratory (SciLifeLab) is a Swedish national center for large-
scale molecular biosciences with focus on health and environmental research, a joint effort 
between Karolinska Institutet, the Royal Institute of Technology (KTH), Stockholm 
University and Uppsala University. Our group has worked extensively to establish a 
collaboration between the Karolinska University Hospital and the SciLifeLab Clinical 
Genomics facility in Stockholm. Bioinformatic tools and workflows have been established, 
enabling implementation of whole genome sequencing (WGS) into healthcare. 
 
Figure 28. The workflow for WGS analysis in the SciLifeLab – Karolinska collaboration 
We decided to perform a proof-of-concept study, to illustrate the potential benefit of rapid 
WGS in acutely presenting neonates with suspected IEM. We used a conceptionally new 
approach where we analyzed pulsed sequence data at different time intervals, shortening the 
procedure to 15-36 hours. 
Three patients were selected, two had known diagnoses and were retrospectively analyzed 
(Propionic acidemia, PA and Pyruvate dehydrogenase deficiency, PDHD) while the third 
patient was recruited from the neonatal intensive care unit (NICU) at Karolinska due to a 






Figure 29. Summary of steps used in the pulsed automated bioinformatic analysis, resulting in a final clinical 
diagnosis within 36 hours. SBS: sequencing by synthesis, nt: nucleotides, Seq: sequencing, Clin: clinical, SE: 
single-end pulse, PE: paired-end pulse. 
After sequencing data was filtered against 474 genes known to be associated with inborn 
errors of metabolism. The patient with PA could be correctly diagnosed at the first pulse 
(single end short reads, 30 nucleotides) after 15 hours. In the patient with PDHD the correct 
diagnosis could be made at the second pulse (single end short reads, 50 nucleotides). In the 
third patient no abnormalities were noted after completion at 36 hours (paired-end long reads, 
100 nucleotides), and the child also had normal findings in the extensive metabolic 




Our center, CMMS, is a specialized clinic for diagnosis of IEM and related rare diseases, 
investigating patients from all over Sweden. We have established a cross-disciplinary 
structure consisting of clinicians from different specialties (pediatrics, neurology, 
endocrinology, clinical chemistry, clinical genetics), biochemists, analytical chemists, 
molecular biologists and bioinformaticians, providing state-of-the art laboratory 
investigations and expert advice on all aspects of IEM. Since 1965, CMMS also runs the 
nation-wide neonatal screening program (“PKU test”), currently offering testing for 25 
different treatable conditions to all ≈120 000 Swedish newborns yearly.  
CMMS has worked in close collaboration with the Clinical Genomics facility at Science for 
Life Laboratory (SciLifeLab) in Stockholm since its start. SciLifeLab is a national, academic 
center for large-scale bioscience with advanced infrastructure and expertise for e.g., whole 
genome sequencing, that was established in 2010. A range of bioinformatic tools and 
workflows have been developed allowing rapid, quality assured, comprehensive, clinical-
grade analyses of WGS data for diagnosis of rare inherited diseases. IEM was particularly 
suitable for initial clinical implementation, due to the multidisciplinary organization of 
CMMS where clinical specialists work closely together with experts in laboratory medicine 
and experimental science. By restricting analyses to rare variants in genes relevant for each 
patient’s individual disease presentation, and by putting genome data into context with 
clinical information and biochemical findings, a manageable number of variants can be 
generated for rapid evaluation by the diagnostic team and translated all the way to 
individualized treatment. The concept has evolved into a cross-clinic collaboration including 
Clinical Genetics and Clinical Immunology enabling sharing of genome data, collaboration 
around unclear cases and diagnostics across a broad range of rare diseases. A new landscape 
of monogenic disorders is thus emerging.  
Up to the end of 2019 we had analyzed more than 3000 patients using WGS, with an overall 
diagnostic yield of 38% across more than 700 different genes. Around 850 of these patients 
were investigated primarily for IEM. Our latest strategy involves a new protocol for 
diagnostics of mitochondrial diseases where we from a muscle biopsy can obtain 
mitochondrial biochemical analysis, light- and electron microscopic studies and, by 
extracting DNA directly from the muscle specimen, simultaneously obtain the sequence of 
both the nuclear and mitochondrial DNA from a single sample. This strategy can be 
employed for muscular dystrophies and other monogenic disorders where information of 
muscle morphology and/or biochemistry from muscle tissue is relevant. In the future we are 
planning to include gene expression analysis by performing sequencing of RNA to increase 
the diagnostic yield even further. 
The major part of my thesis project was carried out before clinical WGS became routinely 
available. Linkage analysis and gene-by-gene sequencing were the methods of choice but 
these have since become mostly obsolete. However, detailed and thorough clinical 
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investigations remain essential both in order to make sense of large datasets, and to 
understand the mechanistic implications of encountered mutations. 
Paper I and II. The disorder sarcoplasmic body myopathy is now renamed myoglobinopathy 
after finding the causative genetic defect almost 40 years after its original description. To date 
six families have been diagnosed with this rare muscle dystrophy. If our assumption that the 
mutation has arisen in a mutational hotspot is true, more families are likely to emerge.  I have 
had the privilege of seeing patients at all disease stages and follow them from 
presymptomatic to onset, progression and, in some cases, to death. Even if no treatment 
currently exists, the finding of the mutation has made presymptomatic diagnosis without 
muscle biopsy and prenatal diagnosis possible. Several mutation-free babies are now born 
from descendants of the family in paper I.  
Paper III. We describe the first two Swedish families with spinocerebellar ataxia type 4, 
constituting the third and fourth families reported. Detailed clinical characterization expands 
the phenotype of this rare disorder significantly. Besides ataxia and peripheral neuropathy 
affected subjects suffer from striking dysautonomia. Motor neuron signs, eye movement 
abnormalities, dystonia and chorea were also found in some patients. The two families in this 
study have a similar phenotype and share the same haplotype on chromosome 16. Since they 
originate from the same area in southern Sweden, we suspect that the families may be related 
and extended haplotype analysis to investigate kinship will be performed. It is also possible 
that the family of Scandinavian origin described by Flanigan et al in 1996 is related to the 
families characterized in paper III. Recently, we identified a likely causative gene in our 
families. Investigations are ongoing to validate this finding. 
Paper IV. Since our publication in 2011, in total 19 cases of ADK deficiency have been 
published (85). Methionine elevation is a characteristic finding but can be intermittent. 
Therapy with methionine restricted food seems to ameliorate the biochemical and liver 
phenotype to some extent, while the effect on seizures and other neurological symptoms is 
unclear (86). To investigate whether the neurological symptoms were due to hepatic 
encephalopathy, Sandau et al (87) constructed mice with selective knockout of ADK in the 
brain. These experiments showed that diminished expression of ADK in the brain led to 
progressive seizures, learning disability and reduced synaptic plasticity in mouse brain. 
Interestingly, adenosine also has endogenous anticonvulsant and neuroprotective properties 
and ADK is a major enzyme for adenosine removal. The effects of ADK are complex since 
overexpression of ADK in astrocytes can provoke seizures and blockage of ADK expression 
can prevent seizures (88). Since primary or secondary phenotypic alterations in astrocytes is 
now believed to be the cause of, or contributing to, epileptogenesis (89) modulation of 
astrocyte adenosine metabolism could be a potential target for treatment. 
Paper V. Rapid whole genome sequencing has an advantage over exome sequencing in that 
there is no time-consuming library preparation step required. Rapid whole genome 
sequencing is a new technology that will improve diagnosis in the NICU department, saving 
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babies’ lives. As the technology continuously improves and can be made at lower cost there 




7 FUTURE PERSPECTIVES 
7.1 MYOGLOBINOPATHY 
The patients affected by myoglobinopathy have repeatedly asked if there might be treatment 
available in the future. I have kept their hope for this opportunity alive and I truly believe a 
treatment strategy could be devised. 
I see two main roads for designing a treatment. The damage to muscle cells and tissue seems 
to be caused by defective oxidation through a toxic gain of function rather than a loss of 
function defect in oxygen binding, NOS regulation etc. If oxidative damage could somehow 
be prevented the disease progression could possibly be prevented or slowed. A second 
possibility would be to use siRNA or antisense oligonucleotides to reduce expression of the 
mutant allele. Development of such a treatment requires a number of experiments (91). Tests 
in cell cultures and one or more animal models must be performed. Then on- and off-target 
effects must be addressed, preferably by a combination of Southern and Western blot and 
RNAseq. Another obstacle is the problem of delivering enough oligonucleotides to the 
muscle in vivo, which must be assessed by measurements of MB RNA and protein from 
muscle biopsies. There are several recent examples of successful development of treatment 
based on selective gene silencing. One example is the development of Givosiran for treatment 
of acute intermittent porphyria(92). The clinical trials leading up to approval of this novel 
drug were done in collaboration with the Swedish Porphyria Centre at CMMS. 
7.2 SPINOCEREBELLAR ATAXIA TYPE 4 
In this autosomal dominant disorder, we have described two affected families and a third 
possible family is under investigation. The disease could be common in Sweden among 
patients with undiagnosed ataxias. Analysis of the custom capture performed has thus far not 
identified the causative mutation, but we are currently investigating a likely causative gene in 
the region on chromosome 16q22.1. Elucidating the genetic background will add another 
solved spinocerebellar ataxia to the list and make genetic testing possible. If the molecular 
mechanisms can be clarified it will likely shed new light and deeper understanding on disease 
pathogenesis, which in turn could result in ways to modulate the process and to develop 
treatment. 
7.3 ADENOSINE KINASE DEFICIENCY 
Further research in this disorder and other conditions affecting adenosine metabolism will 
likely shed new light on the mechanisms involved in epilepsy. 
7.4 RAPID WHOLE GENOME SEQUENCING 
In our center, CMMS, we are already performing WGS in infants acutely sick from a 
suspected metabolic disorder where we deliver results within one week, and sometimes even 
faster. The time until results are obtained will continue to improve as all aspects of the 
process become more evolved, including the sequencing itself, computational speed, 
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improved automation through bioinformatics and as education and recruitment of staff 
involved in the whole chain increases. Rapid, acute WGS-based diagnostics has many 
additional potential uses, apart from finding IEM in newborns. Rare genetic diseases can be 
found across all clinical specialties and can present at essentially all ages. In order to 
implement rapid WGS for diagnostics across all these potential scenarios, healthcare needs to 
adapt by promoting cross-disciplinary collaboration such that genome data is used in a 




8 SVENSK SAMMANFATTNING 
Denna avhandling handlar om att förbättra diagnos och behandling av personer som drabbas 
av sällsynta neurologiska sjukdomar. Diagnos före behandling är en princip som ofta lärs ut 
till medicinstudenter. Men hur ska man göra om diagnos inte kan ställas på grund av att det 
saknas antingen resurser eller kunskap eller om sjukdomen inte ens finns beskriven? De 
sjukdomar som beskrivs i denna avhandling är alla orsakade av defekt i en enda gen. Generna 
är huvudsakligen belägna i kromosomerna i våra cellers kärnor och utgör ritningen för hur 
våra kroppar är konstruerade. Man tror att det finns cirka 20 000 gener i vår arvsmassa och de 
översätts till ett ännu större antal proteiner, eller äggviteämnen, som tar hand om viktiga 
kemiska eller stödjande uppgifter i kroppen. En gen består av en genetisk sekvens, vilken 
utgör en kod bestående av fyra tecken, A, G, C och T. Hos människan är den genetiska koden 
cirka 3 miljarder tecken lång. Vid sjukdomar som orsakas av ett enda fel i en gen, så kallade 
monogena sjukdomar, har det uppstått ett fel i denna kod som i sin tur orsakar fel i funktionen 
av ett eller flera proteiner. Antalet sjukdomar där den genetiska bakgrunden och de 
molekylära mekanismerna är kända har ökat snabbt tack vare utveckling av nya metoder för 
att fastställa den genetiska koden. Numera finns möjlighet att utläsa den genetiska koden i 
alla 20 000 gener samtidigt i en och samma analys. Det finns fortfarande många monogena 
sjukdomar där man inte lyckats hitta den genetiska förklaringen. I mitt doktorandprojekt har 
jag försökt finna den genetiska orsaken till tre olika sällsynta sjukdomar, och i två av fallen 
lyckades detta. Jag och mina kolleger har även lyckats visa vilka effekter det blir i proteinerna 
som respektive gener kodar för. När det gäller den tredje sjukdomen har vi ännu inte nått hela 
vägen fram till en genetisk förklaring, men vi är övertygande om att arbetet kommer att 
lyckas så småningom. 
Framgångarna beror mycket på två olika saker, tillgång modern utrustning för storskaliga 
genetiska analyser och de omfattande resurser som finns tillgängliga på min arbetsplats, 
Centrum för medfödda metabola sjukdomar, CMMS. 
Delarbete I är en detaljerad beskrivning av nio personer i en familj med en sällsynt 
muskelsjukdom, sarkoplasmatisk inklusionskroppsmyopati. Den första beskrivningen av 
sjukdomen var i en svensk familj och den publicerades för 40 år sedan. Delarbete II handlar 
om den genetiska orsaken till sjukdomen där vi visar att orsaken är en förändring i genen som 
kodar för myoglobin. I delarbete II beskrivs ytterligare 5 familjer som visade sig ha exakt 
samma förändring i myoglobingenen. I delarbete II påvisar vi också att skadorna på 
musklerna orsakas av avvikande oxidation. 
Delarbete III ger en detaljerad klinisk beskrivning av 2 familjer som drabbats av en sjukdom 
som orsakar störd funktion i olika delar av nervsystemet. De drabbade personerna har störd 
balans och koordination, ataxi, beroende på att lillhjärnan påverkas. De som har sjukdomen 
har även polyneuropati och autonom dysfunktion. Polyneuropati är en störd funktion i de 
nerver som förmedlar signaler från hjärnan och ryggmärgen ut till övriga kroppen och det 
autonoma nervsystemet styr olika kroppsfunktioner som inte är direkt viljestyrda som till 
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exempel hjärtrytm, tarmfunktion, svettning mm. Genom en så kallad kopplingsanalys, där 
man undersöker vilka kromosomdelar som finns hos de sjuka respektive hos de friska i 
samma familj, kunde vi dra slutsatsen att sjukdomen orsakas av gen som ligger i kromosom 
16 och att det är samma sjukdom, Spinocerebellär ataxi typ 4, som tidigare beskrivits två 
gånger i två olika familjer i Utah och i Tyskland.  Ytterligare studier pågår, men vi har ännu 
inte kunnat hitta den orsakande genen och har därför inte kunnat klarlägga vad som orsakar 
sjukdomssymtomen. 
Delarbete IV handlar om den kliniska, biokemiska och genetiska kartläggningen av en hittills 
okänd sjukdom som medför avvikelser i de biokemiska processerna i kroppen, metabolismen, 
sjukdomen kallas nu adenosinkinasbrist. De två syskonen med denna sjukdom som vi 
undersökte hade en ovanlig biokemisk avvikelse, förhöjt metionin. Efter att ha uteslutit alla 
kända orsaker till högt metionin kunde vi visa att syskonen led av en tidigare okänd defekt i 
den så kallade metionincykeln, där en rad viktiga processer sker. Adenosinkinas är ett protein 
som hör till gruppen enzymer, dvs proteiner som har som uppgift att omvandla ämnen. Vid 
adenosinkinasbrist ansamlas inte bara metionin utan även nedbrytningen av adenosin 
påverkas, vilket får en mängd konsekvenser som i sin tur orsakar sjukdom. 
Delarbete V handlar om hur man kan gå till väga för att snabbt ställa genetisk diagnos hos 
akut sjuka spädbarn på intensivvårdsavdelningar med hjälp av specialanpassad 
helgenomsekvensering. Spädbarn med störningar i metabolismen svarar inte sällan på 
behandling, förutsatt att rätt diagnos kan ställas innan permanenta skador på centrala 
nervsystemet och andra organ har uppträtt. I denna studie visar vi hur en genetisk diagnos kan 
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